The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
Novel PET Tracer Development Program, 2023Development of a PET Tracer for Imaging of Neuroinflammation in Parkinson’s Disease
Study Rationale: Neuroinflammation plays a key role in the degeneration of dopamine-producing neurons and is critical in the pathogenesis of Parkinson’s disease (PD). Positron Emission Tomography (PET...
Translational Pipeline Program, 2023Evaluation of Glunomab, a Novel Immunotherapy for the Treatment of Parkinson’s Disease
Study Rationale: Glunomab is a monoclonal antibody that inhibits a toxic interaction between two proteins recently determined to be involved in the pathology of Parkinson’s disease (PD). Because its...
Translational Pipeline Program, 2023Using Cellular Approaches to Deep Brain Stimulation to Revert Gait Disorders
Study Rationale: Gait deficits in Parkinson’s disease (PD) are not well controlled with existing therapeutic strategies. Episodic gait deficits such as freezing of gait are particularly debilitating...
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Effects of Chemical Modifications on Aggregation of Alpha-synuclein
Study Rationale: Evidence suggests that alpha-synuclein causes the death of neurons in the brains of people with Parkinson’s disease (PD) by forming clusters (or ‘aggregates’) on the surface of...
Biomarkers to Support Therapeutic Trials Program, 2023Blood Test for Stratifying People with Parkinson’s Disease based on Extracellular Vesicles Derived from Neurons
Study Rationale: Parkinson’s disease (PD) and other synucleinopathies are diagnosed based on symptoms and clinical testing. However, these tests can be inaccurate, and postmortem analysis reveals that...
Research Grant, 2023Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for idiopathic Parkinson’s disease: Phase IIa double-blind, randomized controlled trial
Study Rationale: Chronic neuroinflammation plays a critical role in the development and progression of Parkinson’s disease (PD). Neuroinflammation damages the brain microenvironment, disrupts the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.